LSE - Small Logo
LSE - Small Logo

Dipa Patel

September 4th, 2019

The costs of extending drug patent terms on Brazilian health system

0 comments

Estimated reading time: 5 minutes

Dipa Patel

September 4th, 2019

The costs of extending drug patent terms on Brazilian health system

0 comments

Estimated reading time: 5 minutes

Professor Ken Shadlen looks at a recent paper co-written by incoming student in the Department of International Development, Eduardo Mercadante, that looks at the effects that slow patent examination of pharmaceuticals can have on the Brazilian Universal Health System (SUS). 

Patents provide monopolies for 20 years from the date of application. In Brazil, however, a unique provision of the patent law guarantees a minimum of 10 years of patent protection, from the date of grant. This provision is the subject of considerable controversy in Brazil, particularly in the area of pharmaceuticals, where slow patent examination (the patent office often takes longer than 10 years) has led to the extension of monopoly periods of a number of drugs. While commercial alternatives may be available in other countries, in Brazil, because of the extended periods of patent protection, competition is impeded. As a result, this clause has been contested in numerous lawsuits, two of which are to be decided by Brazil’s Supreme Court.

Eduardo Mercadante, incoming MRes/PhD student in the Department of International Development, and colleagues at the Federal University of Rio de Janeiro have undertaken an analysis of the effects that these extensions (and the subsequent lack of competition) can have in terms of the costs imposed on the Brazilian Universal Health System (SUS). The authors calculate that the extension of nine drug patents could cost the SUS £754 million. The study investigated the public procurement of nine drugs: Soliris, Humira, Prezista, Simponi, Sovaldi, Sprycel, Cimzia, Daklinza and Tasigna. They are distributed by SUS in different treatments, such as cancer, HIV, Hepatitis C and autoimmune diseases. Based on international prices of generic or biosimilar versions, it was estimated that four drugs could have their cost to the SUS reduced by 76%, with the acquisition of alternative, less-expensive versions, and overall, without the minimum terms the nine drugs could be acquired at a savings of 56%. Therefore, the study argues that the sustainability of SUS demands that the minimum term clause be nullified, either through administrative reform of the patent office, via reduction in patent prosecution time, or through the judiciary, with decisions by the Supreme Court on the pending cases.

The paper “O custo para o SUS da extensão da vigência de patentes de medicamentos” (by Julia Paranhos, Eduardo Mercadante, and Lia Hasenclever) remains under embargo, though a report on it, including a summary graph, is available here: https://reporterbrasil.org.br/2019/08/conheca-a-lei-que-vai-causar-prejuizo-bilionario-ao-ministerio-da-saude-e-ampliar-lucro-das-farmaceuticas/


Professor Ken Shadlen is Professor in Development Studies and Head of Department in the Department of International Development at the LSE. He works on the comparative and international political economy of development, with a focus on understanding variation in national policy responses to changing global rules. In recent years his research has focused on the global and cross-national politics of intellectual property (IP). He is also the author of Coalitions and Compliance: The Political Economy of Pharmaceutical Patents in Latin America (OUP, 2017).

The views expressed in this post are those of the author and in no way reflect those of the International Development LSE blog or the London School of Economics and Political Science.

About the author

Dipa Patel

Dipa Patel is the Communications and Events Manager for the Department of International Development at LSE. She is also the Managing Editor of the ID at LSE Blog.

Posted In: Featured | Teaching | Topical and Comment

Leave a Reply

Your email address will not be published. Required fields are marked *

RSS Justice and Security Research Programme

RSS LSE’s engagement with South Asia

  • Sri Lanka Goes to the Polls (Again)
    Following the dramatic Presidential elections in September, Sri Lanka is set to elect a new Parliament in mid-November after newly-elected President Anura Dissanayake called snap elections. In this post, the last of our special posts on general elections in South Asia in 2024 (see below for blogposts on Bangladesh, Pakistan and India), Alan Keenan looks […]
  • Chittagong Hill Tracts: Does it Threaten Stability in Bangladesh?
    The Chittagong Hill Tracts have long been an area of social and political unrest in Bangladesh. With India and Myanmar on either side with shared ethnic populations, it is a geopolitical hotspot. Pranab Kumar Panday discusses the unrest in the region, and why it should act as an important reminder to the Interim Government to […]